Europe Diabetes Devices Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The European diabetes devices market covers a broad range of products designed to monitor blood glucose and deliver insulin to patients with type 1 and type 2 diabetes. The market spans the EU-27 countries plus the United Kingdom, Norway, Switzerland, and other European nations, with total market value approaching $9.5 billion in 2025. Blood glucose monitoring devices, including traditional test strips and advanced continuous glucose monitors, together with insulin delivery systems such as pumps and pens, constitute the core product categories.

• •Market valued at approximately $9.5 billion in 2025 across all European countries
• •Includes CGMs, insulin pumps, insulin pens, blood glucose meters, and connected companion apps
• •Regulatory environment shaped by CE marking requirements under the EU Medical Device Regulation (MDR)

The primary driver of market growth is the increasing prevalence of diabetes across Europe, fueled by rising obesity rates, sedentary lifestyles, and an aging population. Type 2 diabetes accounts for the majority of cases, while type 1 diagnoses continue to climb, particularly among pediatric populations. Reimbursement policies across multiple European countries increasingly favor advanced technologies like CGMs for broader patient eligibility, expanding addressable market size.

• •Over 60 million people living with diabetes in Europe according to IDF estimates, with numbers steadily rising
• •Growing adoption of CGM technology beyond insulin-dependent patients to include type 2 diabetes on basal insulin
• •Technological advancements in sensor accuracy, wearability, and integration with insulin pumps enabling closed-loop systems

Western Europe, led by Germany, France, the United Kingdom, Italy, and Spain, accounts for the largest share of market revenue due to higher per-capita healthcare spending and earlier technology adoption. Northern European countries such as Sweden, Denmark, and the Netherlands show strong CGM penetration rates supported by national health systems. Eastern and Southeastern European markets are growing faster on a percentage basis, though from a smaller installed base, as healthcare systems modernize and reimbursement access improves.

• •Germany represents the single largest national market, followed by the UK and France
• •CGM segment growing faster than traditional blood glucose monitoring segment
• •Eastern European markets expanding as healthcare infrastructure and reimbursement broaden

What are the recent trends and outlook?

The market outlook through 2030 remains positive, with integration of artificial intelligence and machine learning into device algorithms expected to improve glycemic outcomes and differentiate products. Patch pumps and tubeless insulin delivery continue to gain traction, while interoperability between devices from different manufacturers is becoming a regulatory priority under the EU MDR and emerging standards. Telehealth adoption accelerated during recent years has also supported remote monitoring of device data, creating additional value from connected diabetes devices.

• •Hybrid closed-loop and fully automated insulin delivery systems expected to accelerate adoption through the decade
• •Interoperability standards and EU regulations pushing for open device ecosystems and data sharing
• •Digital therapeutics and companion software increasingly bundled with hardware as a competitive differentiator